Theravance’s Phase III ampreloxetine study needs dramatic improvement in neurogenic orthostatic …,

Experts said a one-point improvement in this scale is clinically relevant and FDA approvable. However, SEQUOIA will need to demonstrate considerably …, Experts said a one-point improvement in this scale is clinically relevant and FDA approvable. However, SEQUOIA will need to demonstrate considerably …, Read More

Scroll to Top